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REVIEW
Perioperative statin therapy in cardiac 
and non-cardiac surgery: a systematic review 
and meta-analysis of randomized controlled 
trials
Alessandro Putzu1, Carolina Maria Pinto Domingues de Carvalho e Silva2, Juliano Pinheiro de Almeida2, 
Alessandro Belletti3, Tiziano Cassina4, Giovanni Landoni3,5* and Ludhmila Abrahao Hajjar6
Abstract 
Background: The effects of perioperative statin therapy on clinical outcome after cardiac or non-cardiac surgery are 
controversial. We aimed to assess the association between perioperative statin therapy and postoperative outcome.
Methods: Electronic databases were searched up to May 1, 2018, for randomized controlled trials of perioperative 
statin therapy versus placebo or no treatment in adult cardiac or non-cardiac surgery. Postoperative outcomes were: 
myocardial infarction, stroke, acute kidney injury (AKI), and mortality. We calculated risk ratio (RR) or odds ratio (OR) 
and 95% confidence interval (CI) using fixed-effects meta-analyses. We performed meta-regression and subgroup 
analyses to assess the possible influence of statin therapy regimen on clinical outcomes and trial sequential analysis 
to evaluate the risk of random errors and futility.
Results: We included data from 35 RCTs involving 8200 patients. Perioperative statin therapy was associated 
with lower incidence of postoperative myocardial infarction in non-cardiac surgery (OR = 0.44 [95% CI 0.30–0.64], 
p < 0.0001), but not in cardiac surgery (OR = 0.93 [95% CI 0.70–1.24], p = 0.61) (psubgroup = 0.002). Higher incidence of 
AKI was present in cardiac surgery patients receiving perioperative statins (RR = 1.15 [95% CI 1.00–1.31], p = 0.05), 
nonetheless not in non-cardiac surgery (RR = 1.52 [95% CI 0.71–3.26], p = 0.28) (psubgroup = 0.47). No difference in 
postoperative stroke and mortality was present in either cardiac or non-cardiac surgery. However, low risk of bias trials 
performed in cardiac surgery showed a higher mortality with statins versus placebo (OR = 3.71 [95% CI 1.03–13.34], 
p = 0.04). Subgroup and meta-regression analyses failed to find possible relationships between length of statin regi-
mens and clinical outcomes. Trial sequential analysis suggested no firm conclusions on the topic.
Conclusions: Perioperative statins appear to be protective against postoperative myocardial infarction in non-car-
diac surgery and associated with higher AKI in cardiac surgery. Possible positive or even negative effects on mortality 
could not be excluded and merits further investigations. Currently, no randomized evidence supports the systematic 
administration of statins in surgical patients.
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Background
Perioperative complications are still relatively frequent 
in patients undergoing cardiac or non-cardiac surgery, 
and attempts to minimize complications and deaths are 
crucial. Pathophysiological mechanisms behind clinical 
complications may include inflammatory processes after 
surgery.
The knowledge of statin’s pleiotropic and anti-inflam-
matory effects has led to consider perioperative statin a 
potential treatment able to modulate the clinical outcome 
after surgery [1]. Previous studies suggested beneficial 
effects of perioperative statin therapy on postoperative 
outcome after high-risk non-cardiac surgery [2–4], with a 
previous meta-analysis advising that perioperative statin 
therapy decreases the perioperative incidence of mortal-
ity and myocardial infarction in this high-risk population 
[5].
In contrast, growing evidences on perioperative statins 
administration in cardiac surgery suggested neutral or 
even detrimental effects. In facts, two large, high-quality, 
trials randomizing cardiac surgery patients to receive 
perioperative statin or placebo were recently published 
[6, 7]. Perioperative statins did not prevent postoperative 
atrial fibrillation or perioperative myocardial damage, but 
acute kidney injury (AKI) was more common in patients 
receiving statin. All this evidence supported a potential 
neutral or even negative effect of perioperative statin in 
cardiac surgery.
We conducted a systematic review and meta-analysis 
of randomized controlled trials (RCTs) to provide clinical 
guidance of administration of perioperative statin ther-
apy in the perioperative period. We aimed to assess the 
effects on postoperative myocardial infarction, stroke, 
AKI, and mortality in adult cardiac and non-cardiac sur-
gery in patients treated with perioperative statins.
Methods
We performed a systematic review and meta-analysis of 
RCTs, in compliance with Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [8] and the Cochrane methodology [9], and accord-
ing to a pre-published protocol (PROSPERO database, 
CRD42018093997) [10]. A PRISMA checklist is avail-
able in the supplement (eTable 1, Additional file 1). The 
authors had no conflicts of interests.
Search strategy
Two trained investigators (AP and CS) independently 
searched PubMed, the Cochrane Central Register of clin-
ical trials, and EMBASE (last updated on May 1, 2018) 
for appropriate articles. The search strategy for PubMed 
is reported in the supplement (eMethods 1, Additional 
file  1) and was designed to include any RCT ever pub-
lished with perioperative statin therapy compared to con-
trol in adult humans undergoing surgery. In addition, we 
employed backward snowballing (i.e., scanning of refer-
ences of pertinent articles). No language restriction was 
enforced.
Study selection
References, obtained from database and literature 
searches, were examined first at an abstract level inde-
pendently by 2 investigators (AP and CS), with even-
tual divergences resolved by consensus, and then, if 
potentially pertinent, were retrieved as complete arti-
cles. Eligible studies met the following PICOS criteria: 
(1) Population: adult cardiac and non-cardiac surgery 
patients; (2) Intervention: perioperative administration 
of statin therapy; (3) Comparison intervention: placebo 
or no active intervention as control; (4) Outcome: any 
outcome of the present systematic review (see below); (5) 
Study design: RCT. The exclusion criteria were: overlap-
ping populations and pediatric studies. Two authors (AP 
and JP or AB) independently assessed selected studies for 
the analysis, with divergences resolved by consensus with 
a third author (GL).
Data abstraction and study endpoint
Baseline characteristics, procedural, and outcome data 
were abstracted by one author (AP) extracted relevant 
information from each selected study, and these data 
were checked by a second author (JP or AB). Specifi-
cally, we extracted potential sources of significant clini-
cal heterogeneity, such as study design, clinical setting/
indication, statin dose, and control treatment, as well as 
primary study outcomes.
The per-protocol primary outcomes were: postop-
erative MI, postoperative stroke, postoperative AKI, and 
mortality at the longest follow-up available. Post hoc sec-
ondary outcomes were AKI requiring postoperative renal 
replacement therapy (RRT) and AKI not requiring RRT. 
The outcomes were reported as per-author definition. 
We extracted data following the intention-to-treat basis 
whenever possible. Corresponding authors of all eligible 
articles were contacted in case of missing data on out-
comes of interest.
Risk of bias assessment
We used the Cochrane methodology to evaluate the 
methodological quality of each included trial [9]. Each 
trial was finally judged to be of low, unclear, or high 
risk of bias (eMethods 2, Additional file  1). Publication 
bias was assessed by visually inspecting funnel plots for 
pooled analyses containing > 10 studies [9].
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Statistical analysis
The analysis was stratified according to cardiac or non-
cardiac surgery setting. For each outcome, we calcu-
lated the odds ratio (OR) with 95% confidence intervals 
(CI). For common events, pre-defined as frequency of 
the event in the control group > 10%, we calculated risk 
ratio (RR) with 95% CI [9]. A p value equal or less than 
0.05 was considered significant. In case of statistical sig-
nificant results, we calculated the number needed to treat 
(NNT) or number needed to harm (NNH) and 95% CI. 
Heterogeneity was explored by the Cochran Q statistic 
and characterized with I2. We used a fixed-effects model 
in the absence of significant heterogeneity, defined as p 
value > 0.10 and I2 < 50%. In case of significant heteroge-
neity, we employed the random-effects model except if 
few trials dominate the available evidence or if significant 
publication bias was present, since random-effects meta-
analysis, in these contexts, can give inappropriate high 
weight to smaller studies [9].
According to Cochrane methodology [9], we per-
formed subgroup analyses for each outcome in order to 
assess the influence of trials’ risk of bias, including only 
low risk of bias trials or only trials with unclear or high 
risk of bias. Sensitivity analyses were performed changing 
summary statistic (OR, RR, risk difference) and according 
to possible conflicts of interests/funding. Meta-regres-
sion was employed to examine the possible influence of 
statin therapy regimen on clinical outcomes. Subgroup 
analyses were performed on trials that included only 
statin-naïve patients or trials not employing only statin-
naïve patients (trials enrolling a population of chronic 
statin therapy or a mixed population). Subgroup differ-
ences were tested using Chi-square statistics [9]. The 
meta-analysis was performed using Review Manager 
(RevMan [Computer program], version 5.3. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collabora-
tion, 2014). All the analyses were pre-defined [10].
Trial sequential analysis
To control risks of random errors due to sparse data and 
repetitive testing of cumulative data, we performed a per-
protocol fixed-effects trial sequential analysis (TSA). TSA 
is a methodology that combines an information size cal-
culation, representative of the cumulated sample sizes of 
all included trials, with a threshold for a statistically sig-
nificant treatment effect and a threshold for futility of the 
intervention. In particular, TSA pools the required infor-
mation size with trial sequential monitoring boundaries 
which adjust the confidence intervals and decrease type 
I errors [11–13]. In TSA, the inclusion of each trial in 
the meta-analysis is regarded as an interim meta-analysis 
and TSA permits to control the risk for type I and type 
II errors and helps to clarify whether additional trials are 
needed. Conclusions made using TSA show the potential 
to be more consistent than those using traditional meta-
analysis techniques [11–13]. We conducted TSA with the 
purpose to maintain an overall 5% risk of type I error and 
a 10% risk of type II error, at a power of 90%. We assumed 
a relative risk reduction (RRR) or relative risk increase 
(RRI) of 15%, and we derived the control event propor-
tion from low risk of bias trial. The resulting required 
information size was further diversity (D2)-adjusted; in 
case of D2 = 0, we performed a sensitivity analysis assum-
ing a D2 = 25%. We used the TSA software (TSA Viewer 
[Computer program], version 0.9.5.5 Beta, Copenhagen 
Trial Unit, Centre for Clinical Intervention Research, 
Rigshospitalet, 2016).
Results
Study characteristics
The literature search yielded 8376 references of which 35 
RCTs (8200 randomized patients) [2, 3, 6, 7, 14–44] met 
the eligibility criteria and were included in the analysis 
(Fig.  1). Major exclusions are presented in the supple-
ment (eTable 2, Additional file 1). Characteristics of the 
included trials are reported in Table 1 and in eTable 3 in 
the Additional file 1.
Twenty-five trials (4698 patients) included elective 
cardiac surgery patients, with coronary artery bypass 
grafting surgery as the most represented procedure, 
performed in 72.29% of the patients. Ten trials (3502 
patients) were performed in non-cardiac surgery set-
ting [2, 3, 17, 19, 29, 33, 34, 39, 41, 43], in particular: 2 
in elective non-cardiac surgery, 2 trials in elective vascu-
lar surgery, 1 in elective lung resection surgery, 1 in elec-
tive orthopedic surgery, 1 in elective esophagectomy, 1 
in elective colorectal surgery, and 2 in urgent abdominal 
surgery.
Twenty-four trails included exclusively statin-naïve 
patients (4101 patients), 3 trials included patients on 
chronic statin therapy (1080 patients), and 5 trials had 
a mixed population (2810 patients). All trials adminis-
tered statins preoperatively and 19 trials postoperatively. 
Length of preoperative statin treatment ranged from 1 to 
28 days (median 7 days), and the total duration of therapy 
varied from 2 to 45  days (median 7  days). Atorvastatin 
(10–80  mg) was administered in 22 trials, simvastatin 
(20–80 mg) in 6 trials, rosuvastatin (10 and 20 mg) in 5 
trials, pravastatin (40 or 80 mg) in 1 trial, and fluvastatin 
80  mg in 1 trial. Twenty-six trials administered placebo 
as control, and 9 trials administered no intervention as 
control.
Eight trials were judged to be at low risk of bias in all 
bias domains [3, 6, 7, 21, 30, 32, 34, 39]. Five trials scored 
unclear-risk of bias [22, 33, 35, 43, 44], and 22 trials were 
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at high risk of bias (Fig. 2 and eFigure 1, Additional file 1). 
No publication bias was found (eFigure  2–5, Additional 
file 1). Sensitivity analysis according to conflicts of inter-
est or funding was consistent with primary analysis (eRe-
sults 1, Additional file 1).
In 13 cases, we received further outcomes’ data from 
the authors [6, 14, 17, 19–22, 24, 27, 30, 32–34].
Myocardial infarction
The rate of postoperative MI was lower in non-cardiac 
surgery patients randomized to statins (OR = 0.44 [95% 
CI 0.30–0.64], NNT = 36 [95% CI 25–66]). However, 
TSA was not conclusive for a RRR = 15% (OR = 0.44 
[TSA-adjusted 95% CI 0.16–1.19], 18.27% of the infor-
mation size accrued) suggesting the need of further tri-
als for a firm conclusion (eFigure  6, Additional file  1). 
The results were similar when limiting the analysis to 
low risk of bias trials (OR = 0.28 [95% CI 0.13–0.64], 2 
trials and 300 patients) and at sensitivity analyses (eTa-
bles 4 and 5, Additional file 1).
In contrast, no beneficial effects related to sta-
tin administration were found in cardiac surgery 
(OR = 0.93 [95% CI 0.70–1.24], TSA inconclusive) (psub-
group = 0.002) (Fig. 3), with results consistent at second-
ary analyses (eTables 4 and 5, Additional file 1).
Fig. 1 Study flow diagram
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Stroke
No significant difference in postoperative stroke rate 
was found neither in cardiac surgery (OR = 1.10 [95% CI 
0.60–2.03]) nor in non-cardiac surgery (OR = 0.71 [95% 
CI 0.09–5.64]) (Fig. 4), with TSA inconclusive and similar 
results at secondary analyses (eTable 4, Additional file 1).
Acute kidney injury and renal replacement therapy
Perioperative statins were associated with higher inci-
dence of AKI when compared to control in cardiac sur-
gery patients (11 trials and 3384 patients, RR = 1.15 
[95% CI 1.00–1.31], NNH = 40 [95% CI NNH = 19 to 
NNT = 866]) (Fig.  5), also when limiting the analysis to 
low risk of bias trials (1.17 [95% CI 1.02–1.34], NNH = 30 
[95% CI 16–307]) (eTable 4, Additional file 1). At sensi-
tivity analysis, the effect was not evident when employ-
ing a random-effects model (all trials: RR = 1.05 [95% CI 
0.85–1.30]) or when limiting the analysis to statin-naïve 
patients (RR = 1.09 [95% CI 0.75–1.57]). Trial sequential 
analysis was inconclusive for a RRI = 15% due to the too 
small cumulative information size (eTable  4, Additional 
file 1).
No significant effect was found in non-cardiac surgery 
population (RR = 1.52 [95% CI 0.71–3.26], TSA inconclu-
sive) (Fig. 4), but only 3 trials (239 patients) reported the 
outcome, with all the events coming from 1 trial [19].
In cardiac surgery, no significant difference in postop-
erative RRT was found (OR = 1.46 [95% CI 0.75–2.81]), 
while AKI not requiring RRT was higher in the statin 
group (OR = 1.22 [95% CI 1.02–1.46]) (pgroups = 0.61) 
(eTable 4, Additional file 1). No trials performed in non-
cardiac surgery reported these outcomes.
Mortality
The administration of perioperative statin therapy was 
associated with no significant difference in mortal-
ity in both study population, at a median follow-up of 
30-days (Fig.  6). However, when assessing only lower 
risk of bias trials, perioperative statins were associated 
with increased mortality in the cardiac surgery popula-
tion (OR = 3.71 [95% CI 1.03–13.34], NNH = 181 [95% 
CI 97–1187]) (eTable 4, Additional file 1). Trial sequential 
analysis suggested no firm evidence for a RRI = 15% and 
the need of further randomized trials.
Clinical outcomes and statin regimen
In statin-naïve patients undergoing cardiac surgery, 
perioperative statins are associated with no significant 
differences in all the assessed outcomes (eTable 6, Addi-
tional file  1). Trials enrolling chronic statin users or a 
mixed population showed that perioperative statins are 
Fig. 2 Risk of bias summary: review authors’ judgments about each 
risk of bias item for each included study
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associated with a higher risk of AKI in cardiac surgery 
(RR = 1.16 [95% CI 1.00–1.34]) and no differences in 
other outcomes (eTable 6, Additional file 1).
In non-cardiac surgery, lower myocardial infarction is 
evident in both statin-naïve (OR = 0.49 [95% CI 0.30–
0.81]) and chronic statin patients (OR = 0.37 [95% CI 
0.21–0.67]), and no differences in other outcomes (eTa-
ble  6, Additional file  1). No significant between-groups 
differences were found between statin-naïve trials and 
other trials enrolling patients on chronic statin therapy or 
a mixed population (pgroups > 0.05) (eTable  6, Additional 
file 1).
Meta-regression analysis failed to find possible rela-
tionships between length of pre- or postoperative statin 
regimen and clinical outcomes (eResults 2, Additional 
file 1).
Discussion
Our systematic review and meta-analysis suggests that 
perioperative statin therapy could be protective against 
postoperative myocardial infarction in non-cardiac sur-
gery but associated with an increased risk of acute kidney 
injury in cardiac surgery. Statins were associated with an 
increase in hospital mortality in cardiac surgery in low 
Fig. 3 Postoperative myocardial infarction (MI). Forest plot for postoperative MI in patients with perioperative statin therapy versus control
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risk of bias trials. However, the quality and quantity of 
randomized evidence are still insufficient to allow a firm 
conclusion on the topic.
This is the largest and most comprehensive meta-analy-
sis of RCTs of statins in surgery performed so far, includ-
ing 35 randomized trials and 8200 patients, evaluating 
the effect of statin therapy on outcomes in both non-car-
diac and cardiac surgery using separate analysis. In non-
cardiac surgery, a previous meta-analysis that evaluated 
5 RCTs in vascular surgery did not show any detrimental 
or favorable effect of statins on postoperative outcomes 
[45]. De Waal et al., in a meta-analysis of 16 trials, only 
included statin-naïve patients undergoing surgery and 
showed that starting statin therapy, in this cohort of 
patients who were not already on long-term statin treat-
ment, reduces perioperative mortality, myocardial infarc-
tion, atrial fibrillation, and decreases length of hospital 
stay [5]. Our study is consistent with previous findings 
regarding prevention in postoperative myocardial infarc-
tion, but we failed to find any other possible beneficial 
effects, even in the statin-naïve subgroup. On the other 
hand, a recent meta-analysis evaluated 23 trials in cardiac 
surgery and showed no effect of statin on postoperative 
incidence of myocardial infarction, infection, stroke, and 
atrial fibrillation, and a higher occurrence of AKI [46].
A potential beneficial effect of perioperative statins 
on postoperative MI in non-cardiac surgery was found, 
in contraposition to the lack of effects in cardiac sur-
gery patients. Regarding non-cardiac surgery, a rand-
omized study suggested that a short-term treatment 
with atorvastatin significantly reduces the incidence of 
major adverse cardiovascular events after vascular sur-
gery [2]. In contrast, a more recent and larger trial found 
neutral results and did not demonstrate a reduction in 
major cardiovascular complications after a short-term 
perioperative course of statin in statin-naïve non-car-
diac surgery patients, even in the vascular surgery sub-
group [19]. Chopra and colleagues, in a meta-analysis 
published in 2012 including 15 RCTs with 2292 patients 
undergoing cardiac and non-cardiac surgeries, found that 
perioperative statin treatment reduced the risk of myo-
cardial infarction [4]. Nowadays, the growing quality and 
Fig. 4 Postoperative stroke. Forest plot for postoperative stroke in patients with perioperative statin therapy versus control
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quantity of data can allow a more thoughtful analysis, 
confirming the potential benefits of statin in non-cardiac 
surgery in terms of MI prevention, but not in cardiac 
surgery. In fact, in the largest RCTs performed so far in 
cardiac surgery patients, no difference was found in post-
operative MI and myocardial injury [6, 7]. Periopera-
tive myocardial ischemia in non-cardiac surgery occurs 
mostly as consequence of endogenous catecholamine 
release and acute inflammatory response, resulting in 
an increased oxygen demand, heart rate, and contractil-
ity. Inflammation also leads to changes in atheromatous 
plaque features, culminating in the rupture of lipid-laden 
vulnerable lesions, thrombocytes activation with devel-
opment of platelet-rich thrombi, acute vessel occlusion, 
and ischemia [47, 48]. Perioperative statins might reduce 
the risk of perioperative infarction due to its properties 
of endothelial modulation resulting in vasodilation in 
addition to its anti-inflammatory effects, reducing plaque 
instability [49]. In cardiac surgery, myocardial infarc-
tion occurs mainly due to an ischemic event arising from 
either a failure in graft function, an acute coronary event 
involving the native coronary arteries, or inadequate car-
dioprotection during cardiopulmonary bypass. We might 
postulate that the different pathophysiology mechanisms 
could explain our findings of no protection of statins 
against MI after cardiac surgery. In addition, our findings 
showed no effect of perioperative statin in postopera-
tive stroke, another crucial cardiovascular complication. 
However, further investigations are warranted in patients 
at high risk of cerebrovascular events.
Our systematic review, including 25 studies in cardiac 
surgery, of whom 5 with low risk of bias, confirms the 
previous findings of possible negative effects of statins 
on renal function of cardiac surgery patients. For many 
years, perioperative statins were considered an attrac-
tive therapy for preventing AKI following cardiac sur-
gery, hypothesis based mainly on the positive results 
from retrospective series or high risk of bias RCTs [50]. 
Nowadays, high-quality RCTs support the lack of a kid-
ney-protective effect [6, 7, 30]. The largest RCT showed 
that rosuvastatin therapy resulted in a significantly higher 
rate of AKI and plasma creatinine compared to placebo 
at 48  h after cardiac surgery [7]. Similarly, the second 
largest RCT published so far showed a non-significant 
trend in favor of placebo and a possible harmful effect of 
perioperative statins in the small subgroup of statin-naïve 
patients with chronic kidney disease [6]. The exact mech-
anisms of increased occurrence of AKI related to sta-
tin use need to be elucidated. There are possible effects 
of statin in kidney function, including mitochondrial 
Fig. 5 Postoperative acute kidney injury (AKI). Forest plot for postoperative AKI in patients with perioperative statin therapy versus control
Page 12 of 14Putzu et al. Ann. Intensive Care  (2018) 8:95 
dysfunction leading to overall cellular energy imbalance 
[50–52]. Further research is needed, especially in the 
non-cardiac surgery setting, where evidence is still lim-
ited, not allowing any conclusion on possible renal effects 
of statin in this population.
Strengths and limitations
Our study has some limitations, which most of them are 
characteristics of all aggregate data meta-analyses [53]. 
Different statin dosages and formulations were used 
as statin therapy in the included studies. We did not 
perform subgroup analysis of different types of periopera-
tive statin regimens, since most of the trials administered 
different statin dose and formulation for different length 
of time, and the analysis would be underpowered and 
mainly driven by results of small and higher risk of bias 
trials. Another limitation is that only few high-quality 
randomized trials have been published so far in non-car-
diac surgery setting. To assess the effects of methodologi-
cal biases on results [54], we assessed subgroup analyses 
according to trial risk of bias. A major strength of this 
meta-analysis is that we assessed the most important 
Fig. 6 Postoperative mortality. Forest plot for postoperative short-term mortality in patients with perioperative statin therapy versus control (the 
longest follow-up available, median 30 days)
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clinical outcome, mortality. We decided not to assess sur-
rogate outcomes commonly related to statin administra-
tion, such as myalgia or creatinine kinase elevation, due 
to the heterogeneity in definitions and spurious report-
ing. Finally, most of the included trials were focused on 
perioperative period and did not report clinical outcomes 
at longer follow-up.
Further high-quality trials should systematically evalu-
ate the relationship between postoperative outcomes and 
patients’ variables (e.g., statin-naïve, chronic kidney dis-
ease), to the surgery, and to the statin regimen (e.g., ther-
apy duration).
Conclusions
Our results suggest that perioperative statins appear to 
be protective against postoperative myocardial infarction 
in non-cardiac surgery and associated with an increased 
risk of acute kidney injury in cardiac surgery. There are 
still insufficient randomized data for firm conclusions on 
perioperative statin therapy, and possible positive or even 
negative effects on mortality could not be excluded. No 
randomized evidence supports the systematic adminis-
tration of statins in surgical patients, especially in statin-
naïve patients. Further RCTs should evaluate the safety 
profile, possible beneficial effects on patients’ outcome, 
particularly in non-cardiac surgery, and assess the more 
appropriate time-point for eventual statin discontinu-
ation before surgery in patients under chronic statin 
therapy.
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